• Guest - w'd love to know what you think about the forum! Take the 2025 Survey »

Does Canagliflozin AKA Invokana cause artery blockage in long term use?

K

kf6wax

Newbie
Messages
3
Type of diabetes
Type 2
Treatment type
Tablets (oral)
Hi, I have type 2 diabetes and was diagnosed with it in 2011.
I recently was told an artery in my leg was blocked and told to stop taking the Canaglifozin immediately as this was the cause
of my artery blockage. No other Doctor or vascular consultant has heard of this side effect and I wondered if anyone else had heard of this other than myself?

My blood sugar in the morning test has jumped from high 8 to 10 or 11 having stopped this drug, anyone care to share their experience with this drug please?
 
Thank you @Kenny A for your swift response, I am having a Diabetes review in about 1 weeks time and I will bring
this up with the Doctor's
 
@Kenny, Since you provided the link above I have made my Dr's surgery aware of the link to the article you provided and they immediately withdrew this drug from my list of prescibed drugs. Nobody except one vascular specialist was aware of the issue with Canagliflozin and it sounds like the company who make this drug may be liable for a class action lawsuit! I am at immediate risk of limb amputation and Canagliflozin AKA INVOKANA is likely the reason for this, thanks again @Kenny
 
No problem. I hope all goes well with you.

Best of luck.
 
KennyA said:
No problem. I hope all goes well with you.

Best of luck.
Click to expand...
Should this be a concern to those of us prescribed Dapagliflozin? I looked up Canaglflozin's bad side effects and it includes burning urine, which I, on Dapagliflozin, have been suffering from for 3 months, with no UTI and no diagnosis.
 
Last edited:
Hmm, this paper says not???

Patients with versus without PAD are at a higher risk of CV death of CV death, HHF, and kidney outcomes, and have a consistent benefits for CV death/HHF and progression of kidney disease with dapagliflozin. Patients with PAD had a higher risk of limb events, with no consistent pattern of incremental risk observed with dapagliflozin

and this from the UK government

SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)

Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes.
www.gov.uk
Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes.
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn More.…